The research company Hamlet Biopharma reports, as planned, no revenue for the second quarter. The operating loss increased.The operating result was SEK -15.1 million (-14.0). The result after tax was SEK -15.4 million (-14.4). Cash and cash equivalents amounted to SEK -23.6 million (-19.2)."To date, the company has conducted three successful phase II studies with a budget of approximately SEK 250 million, including the cancer project with 'Fast Track' and news about pivotal studies from the FDA in the USA, as well as the successful development of alternatives to antibiotics. We believe these results should sustain investors' confidence in the company's ability to achieve strategic goals at low cost and high quality. We want to thank our multinational team, as well as our external partners and collaboration partners, who are behind the successes and remain a resource for the future. We are grateful for the strong support from investors and will continue to use our capital efficiently for the optimal development and commercialization of our pharmaceuticals," writes the company. Hamlet Biopharma, SEK mQ2-2025/2026Q2-2024/2025Net sales00Operating result-15.1-14.0Result before tax-15.4-14.5Net result-15.4-14.4Cash and cash equivalents-23.6-19.2